Alzheimer Disease/Dementia

The program's interventions enhanced cognitive function in older adults at risk for dementia, highlighting the importance of healthy behaviors.

The ability to observe an early marker of Alzheimer disease progression noninvasively marks a new phase of research with potential for improved disease management.

Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.

Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.

Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.

The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.